<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29679372</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>09</Month>
        <Day>01</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>09</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1365-2990</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>45</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Neuropathology and applied neurobiology</Title>
          <ISOAbbreviation>Neuropathol Appl Neurobiol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Paraneoplastic cerebellar degeneration: Yo antibody alters mitochondrial calcium buffering capacity.</ArticleTitle>
        <Pagination>
          <StartPage>141</StartPage>
          <EndPage>156</EndPage>
          <MedlinePgn>141-156</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/nan.12492</ELocationID>
        <Abstract>
          <AbstractText Label="AIM">Neurodegeneration is associated with dysfunction of calcium buffering capacity and thereby sustained cellular and mitochondrial calcium overload. Paraneoplastic cerebellar degeneration (PCD), characterized by progressive Purkinje neurone degeneration following paraneoplastic Yo antibody internalization and binding to cerebellar degeneration-related protein CDR2 and CDR2L, has been linked to intracellular calcium homeostasis imbalance due to calbindin D<sub>28k</sub> malfunction. Therefore, we hypothesized that Yo antibody internalization affects not only calbindin calcium binding capacity, but also calcium-sensitive mitochondrial-associated signalling, causing mitochondrial calcium overload and thereby Purkinje neurone death.</AbstractText>
          <AbstractText Label="METHODS">Immunohistochemically, we evaluated cerebellar organotypic slice cultures of rat brains after inducing PCD through the application of Yo antibody-positive PCD patient sera or purified antibodies against CDR2 and CDR2L how pharmacologically biased mitochondrial signalling affected PCD pathology.</AbstractText>
          <AbstractText Label="RESULTS">We found that Yo antibody internalization into Purkinje neurons caused depletion of Purkinje neurone calbindin-immunoreactivity, cannabinoid 1 receptor over-activation and alterations in the actions of the mitochondria permeability transition pore (MPTP), voltage-dependent anion channels, reactive oxygen species (ROS) and Na<sup>+</sup> /Ca<sup>2+</sup> exchangers (NCX). The pathological mechanisms caused by Yo antibody binding to CDR2 or CDR2L differed between the two targets. Yo-CDR2 binding did not alter the mitochondrial calcium retention capacity, cyclophilin D-independent opening of MPTP or activity of NCX.</AbstractText>
          <AbstractText Label="CONCLUSION">These findings suggest that minimizing intracellular calcium overload toxicity either directly with cyclosporin-A or indirectly with cannabidiol or the ROS scavenger butylated hydroxytoluene promotes mitochondrial calcium homeostasis and may therefore be used as future neuroprotective therapy for PCD patients.</AbstractText>
          <CopyrightInformation>© 2018 The Authors. Neuropathology and Applied Neurobiology published by John Wiley &amp; Sons Ltd on behalf of British Neuropathological Society.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Panja</LastName>
            <ForeName>D</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Medicine (K1), University of Bergen, Bergen, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vedeler</LastName>
            <ForeName>C A</ForeName>
            <Initials>CA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Clinical Medicine (K1), University of Bergen, Bergen, Norway.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Haukeland University Hospital, Bergen, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schubert</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0003-3592-2470</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Haukeland University Hospital, Bergen, Norway.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>05</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Neuropathol Appl Neurobiol</MedlineTA>
        <NlmUniqueID>7609829</NlmUniqueID>
        <ISSNLinking>0305-1846</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>SY7Q814VUP</RegistryNumber>
          <NameOfSubstance UI="D002118">Calcium</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002526" MajorTopicYN="N">Cerebellar Diseases</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002531" MajorTopicYN="N">Cerebellum</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020362" MajorTopicYN="N">Paraneoplastic Cerebellar Degeneration</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011689" MajorTopicYN="N">Purkinje Cells</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">calcium homeostasis</Keyword>
        <Keyword MajorTopicYN="Y">calcium-sensitive mitochondrial-associated signalling</Keyword>
        <Keyword MajorTopicYN="Y">cerebellar degeneration-related proteins CDR2 and CDR2L</Keyword>
        <Keyword MajorTopicYN="Y">paraneoplastic Yo antibody</Keyword>
        <Keyword MajorTopicYN="Y">paraneoplastic cerebellar degeneration</Keyword>
      </KeywordList>
      <CoiStatement>No conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>4</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>4</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>4</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29679372</ArticleId>
        <ArticleId IdType="pmc">PMC7379599</ArticleId>
        <ArticleId IdType="doi">10.1111/nan.12492</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Storstein A, Vedeler CA. Paraneoplastic neurological syndromes and onconeural antibodies: clinical and immunological aspects. Adv Clin Chem
2007; 44: 143–85
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17682342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jarius S, Wildemann B. ‘Medusa head ataxia’: the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 3: anti‐Yo/CDR2, anti‐Nb/AP3B2, PCA‐2, anti‐Tr/DNER, other antibodies, diagnostic pitfalls, summary and outlook. J Neuroinflammation
2015; 12: 166
10.1186/s12974-015-0358-9
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12974-015-0358-9</ArticleId>
            <ArticleId IdType="pmc">PMC4573944</ArticleId>
            <ArticleId IdType="pubmed">26377319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Storstein A, Krossnes BK, Vedeler CA. Morphological and immunohistochemical characterization of paraneoplastic cerebellar degeneration associated with Yo antibodies. Acta Neurol Scand
2009; 120: 64–7
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19486326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Albert ML, Darnell JC, Bender A, Francisco LM, Bhardwaj N, Darnell RB. Tumor‐specific killer cells in paraneoplastic cerebellar degeneration. Nat Med
1998; 4: 1321–4
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9809559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Carpenter EL, Vance BA, Klein RS, Voloschin A, Dalmau J, Vonderheide RH. Functional analysis of CD8+ T cell responses to the onconeural self protein cdr2 in patients with paraneoplastic cerebellar degeneration. J Neuroimmunol
2008; 193: 173–82
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18053582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Santomasso BD, Roberts WK, Thomas A, Williams T, Blachère NE, Dudley ME, Houghton AN, Posner JB, Darnell RB. A T‐cell receptor associated with naturally occurring human tumor immunity. Proc Natl Acad Sci U S A
2007; 104: 19073–8
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2141910</ArticleId>
            <ArticleId IdType="pubmed">18045792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sutton IJ, Steele J, Savage CO, Winer JB, Young LS. An interferon‐gamma ELISPOT and immunohistochemical investigation of cytotoxic T lymphocyte‐mediated tumour immunity in patients with paraneoplastic cerebellar degeneration and anti‐Yo antibodies. J Neuroimmunol
2004; 150: 98–106
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15081253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dahm L, Ott C, Steiner J, Stepniak B, Teegen B, Saschenbrecker S, Hammer C, Borowski K, Begemann M, Lemke S, Rentzsch K. Seroprevalence of autoantibodies against brain antigens in health and disease: brain‐Targeting Autoantibodies. Ann Neurol
2014; 76: 82–94
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24853231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Diamond B, Huerta PT, Mina‐Osorio P, Kowal C, Volpe BT. Losing your nerves? Maybe it's the antibodies. Nat Rev Immunol
2009; 9: 449–56
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2783680</ArticleId>
            <ArticleId IdType="pubmed">19424277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Roberts WK, Darnell RB. Neuroimmunology of the paraneoplastic neurological degenerations. Curr Opin Immunol
2004; 16: 616–22
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15342008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Storstein A, Monstad SE, Honnorat J, Vedeler CA. Paraneoplastic antibodies detected by isoelectric focusing of cerebrospinal fluid and serum. J Neuroimmunol
2004; 155: 150–4
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15342206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Eichler TW, Totland C, Haugen M, Qvale TH, Mazengia K, Storstein A, Haukanes BI, Vedeler CA. CDR2L antibodies: a new player in paraneoplastic cerebellar degeneration. PLoS ONE
2013; 8: e66002
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3688866</ArticleId>
            <ArticleId IdType="pubmed">23823982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Totland C, Aarskog NK, Eichler TW, Haugen M, Nøstbakken JK, Monstad SE, Salvesen HB, Mørk S, Haukanes BI, Vedeler CA. CDR2 antigen and Yo antibodies. Cancer Immunol Immunother
2011; 60: 283–9
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3024499</ArticleId>
            <ArticleId IdType="pubmed">21080165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Darnell JC, Albert ML, Darnell RB. Cdr2, a target antigen of naturally occuring human tumor immunity, is widely expressed in gynecological tumors. Cancer Res
2000; 60: 2136–9
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10786675</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Raspotnig M, Haugen M, Thorsteinsdottir M, Stefansson I, Salvesen HB, Storstein A, Vedeler CA. Cerebellar degeneration‐related proteins 2 and 2‐like are present in ovarian cancer in patients with and without Yo antibodies. Cancer Immunol Immunother
2017; 66: 1463–71
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28710511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rodriguez M, Truh LI, O'Neill BP, Lennon VA. Autoimmune paraneoplastic cerebellar degeneration: ultrastructural localization of antibody‐binding sites in Purkinje cells. Neurology
1988; 38: 1380–6
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3045692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Okano HJ, Park WY, Corradi JP, Darnell RB. The cytoplasmic Purkinje onconeural antigen cdr2 down‐regulates c‐Myc function: implications for neuronal and tumor cell survival. Genes Dev
1999; 13: 2087–97
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC316965</ArticleId>
            <ArticleId IdType="pubmed">10465786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Corradi JP, Yang C, Darnell JC, Dalmau J, Darnell RB. A post‐transcriptional regulatory mechanism restricts expression of the paraneoplastic cerebellar degeneration antigen cdr2 to immune privileged tissues. J Neurosci
1997; 17: 1406–15
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6793730</ArticleId>
            <ArticleId IdType="pubmed">9006982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sakai K, Mitchell DJ, Tsukamoto T, Steinman L. Isolation of a complementary DNA clone encoding an autoantigen recognized by an anti‐neuronal cell antibody from a patient with paraneoplastic cerebellar degeneration. Ann Neurol
1991; 30: 738
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1763903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schubert M, Panja D, Haugen M, Bramham CR, Vedeler CA. Paraneoplastic CDR2 and CDR2L antibodies affect Purkinje cell calcium homeostasis. Acta Neuropathol
2014; 128: 835–52
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4231287</ArticleId>
            <ArticleId IdType="pubmed">25341622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hwang JY, Lee J, Oh CK, Kang HW, Hwang IY, Um JW, Park HC, Kim S, Shin JH, Park WY, Darnell RB. Proteolytic degradation and potential role of onconeural protein cdr2 in neurodegeneration. Cell Death Dis
2016; 7: e2240
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5143381</ArticleId>
            <ArticleId IdType="pubmed">27253404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bhosale G, Sharpe JA, Sundier SY, Duchen MR. Calcium signaling as a mediator of cell energy demand and a trigger to cell death: mitochondrial calcium signaling. Ann N Y Acad Sci
2015; 1350: 107–16
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4949562</ArticleId>
            <ArticleId IdType="pubmed">26375864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Brini M, Calì T, Ottolini D, Carafoli E. Neuronal calcium signaling: function and dysfunction. Cell Mol Life Sci
2014; 71: 2787–814
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24442513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lee J. Mitochondrial drug targets in neurodegenerative diseases. Bioorg Med Chem Lett
2016; 26: 714–20
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26806044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Graier WF, Frieden M, Malli R. Mitochondria and Ca2+ signaling: old guests, new functions. Pflüg Arch – Eur J Physiol
2007; 455: 375–96
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4864527</ArticleId>
            <ArticleId IdType="pubmed">17611770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Araújo IM, Carreira BP, Pereira T, Santos PF, Soulet D, Inácio â, Bahr BA, Carvalho AP, Ambrósio AF, Carvalho CM. Changes in calcium dynamics following the reversal of the sodium‐calcium exchanger have a key role in AMPA receptor‐mediated neurodegeneration via calpain activation in hippocampal neurons. Cell Death Differ
2007; 14: 1635–46
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17585341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Görlach A, Bertram K, Hudecova S, Krizanova O. Calcium and ROS: a mutual interplay. Redox Biol
2015; 6: 260–71
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4556774</ArticleId>
            <ArticleId IdType="pubmed">26296072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schwaller B, Meyer M, Schiffmann S. ‘New’ functions for ‘old’ proteins: the role of the calcium‐binding proteins calbindin D‐28k, calretinin and parvalbumin, in cerebellar physiology. Studies with knockout mice. Cerebellum Lond Engl
2002; 1: 241–58
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12879963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Laure‐Kamionowska M, Maślińska D. Calbindin positive Purkinje cells in the pathology of human cerebellum occurring at the time of its development. Folia Neuropathol
2009; 47: 300–5
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20054781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Palop JJ, Jones B, Kekonius L, Chin J, Yu G‐Q, Raber J, Masliah E, Mucke L. Neuronal depletion of calcium‐dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease‐related cognitive deficits. Proc Natl Acad Sci U S A
2003; 100: 9572–7
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC170959</ArticleId>
            <ArticleId IdType="pubmed">12881482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Barski JJ, Hartmann J, Rose CR, Hoebeek F, Mörl K, Noll‐Hussong M, De Zeeuw CI, Konnerth A, Meyer M. Calbindin in cerebellar Purkinje cells is a critical determinant of the precision of motor coordination. J Neurosci
2003; 23: 3469–77
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6742296</ArticleId>
            <ArticleId IdType="pubmed">12716955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bastianelli E. Distribution of calcium‐binding proteins in the cerebellum. Cerebellum Lond Engl
2003; 2: 242–62
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14964684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Greenlee JE. Treatment of paraneoplastic cerebellar degeneration. Curr Treat Options Neurol
2013; 15: 185–200
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7102346</ArticleId>
            <ArticleId IdType="pubmed">23315179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ward MW, Huber HJ, Weisova P, Dussmann H, Nicholls DG, Prehn JHM. Mitochondrial and plasma membrane potential of cultured cerebellar neurons during glutamate‐induced necrosis, apoptosis, and tolerance. J Neurosci
2007; 27: 8238–49
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6673046</ArticleId>
            <ArticleId IdType="pubmed">17670970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kenwood BM, Weaver JL, Bajwa A, Poon IK, Byrne FL, Murrow BA, Calderone JA, Huang L, Divakaruni AS, Tomsig JL, Okabe K. Identification of a novel mitochondrial uncoupler that does not depolarize the plasma membrane. Mol Metab
2014; 3: 114–23
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3953706</ArticleId>
            <ArticleId IdType="pubmed">24634817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Brana C, Benham C, Sundstrom L. A method for characterising cell death in vitro by combining propidium iodide staining with immunohistochemistry. Brain Res Brain Res Protoc
2002; 10: 109–14
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12431710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Noraberg J, Kristensen BW, Zimmer J. Markers for neuronal degeneration in organotypic slice cultures. Brain Res Brain Res Protoc
1999; 3: 278–90
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9974143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zou JY, Crews FT. TNF alpha potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NF kappa B inhibition. Brain Res
2005; 1034: 11–24
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15713255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Petitet F, Jeantaud B, Reibaud M, Imperato A, Dubroeucq MC. Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta9‐tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci
1998; 63: PL1–6
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9667767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ashton JC, Appleton I, Darlington CL, Smith PF. Immunohistochemical localization of cannabinoid CB1 receptor in inhibitory interneurons in the cerebellum. Cerebellum Lond Engl
2004; 3: 222–6
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15686100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ibeas Bih C, Chen T, Nunn AVW, Bazelot M, Dallas M, Whalley BJ. Molecular targets of cannabidiol in neurological disorders. Neurother J Am Soc Exp Neurother
2015; 12: 699–730
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4604182</ArticleId>
            <ArticleId IdType="pubmed">26264914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ruiz A, Alberdi E, Matute C. CGP37157, an inhibitor of the mitochondrial Na+/Ca2+ exchanger, protects neurons from excitotoxicity by blocking voltage‐gated Ca2+ channels. Cell Death Dis
2014; 5: e1156
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5424111</ArticleId>
            <ArticleId IdType="pubmed">24722281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Brustovetsky T, Brittain MK, Sheets PL, Cummins TR, Pinelis V, Brustovetsky N. KB‐R7943, an inhibitor of the reverse Na+/Ca2+ exchanger, blocks N‐methyl‐d‐aspartate receptor and inhibits mitochondrial complex I. Br J Pharmacol
2011; 162: 255–70
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3012420</ArticleId>
            <ArticleId IdType="pubmed">20883473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wiczer BM, Marcu R, Hawkins BJ. KB‐R7943, a plasma membrane Na+/Ca2+ exchanger inhibitor, blocks opening of the mitochondrial permeability transition pore. Biochem Biophys Res Commun
2014; 444: 44–9
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3951502</ArticleId>
            <ArticleId IdType="pubmed">24434143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cho S, Wood A, Bowlby MR. Brain slices as models for neurodegenerative disease and screening platforms to identify novel therapeutics. Curr Neuropharmacol
2007; 5: 19–33
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2435340</ArticleId>
            <ArticleId IdType="pubmed">18615151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lossi L, Alasia S, Salio C, Merighi A. Cell death and proliferation in acute slices and organotypic cultures of mammalian CNS. Prog Neurobiol
2009; 88: 221–45
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19552996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ling C, Verbny YI, Banks MI, Sandor M, Fabry Z. In situ activation of antigen‐specific CD8+ T cells in the presence of antigen in organotypic brain slices. J Immunol
2008; 180: 8393–9
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3338102</ArticleId>
            <ArticleId IdType="pubmed">18523307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kim JH. Overexpression of calbindin‐D28K in hippocampal progenitor cells increases neuronal differentiation and neurite outgrowth. FASEB J
2006; 20: 109–11. 10.1096/fj.05-4826fje
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1096/fj.05-4826fje</ArticleId>
            <ArticleId IdType="pubmed">16278289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ghoumari AM, Dusart I, El‐Etr M, Tronche F, Sotelo C, Schumacher M, Baulieu E‐E. Mifepristone (RU486) protects Purkinje cells from cell death in organotypic slice cultures of postnatal rat and mouse cerebellum. Proc Natl Acad Sci U S A
2003; 100: 7953–8
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC164694</ArticleId>
            <ArticleId IdType="pubmed">12810951</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kawamata T, Taniguchi T, Mukai H, Kitagawa M, Hashimoto T, Maeda K, Ono Y, Tanaka C. A protein kinase, PKN, accumulates in Alzheimer neurofibrillary tangles and associated endoplasmic reticulum‐derived vesicles and phosphorylates tau protein. J Neurosci
1998; 18: 7402–10
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6793236</ArticleId>
            <ArticleId IdType="pubmed">9736660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Takanaga H, Mukai H, Shibata H, Toshimori M, Ono Y. PKN interacts with a paraneoplastic cerebellar degeneration‐associated antigen, which is a potential transcription factor. Exp Cell Res
1998; 241: 363–72
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9637778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Angelova PR, Abramov AY. Role of mitochondrial ROS in the brain: from physiology to neurodegeneration. FEBS Lett
2018; 592: 692–702. 10.1002/1873-3468.12964
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1873-3468.12964</ArticleId>
            <ArticleId IdType="pubmed">29292494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gajavelli S, Sinha VK, Mazzeo AT, Spurlock MS, Lee SW, Ahmed AI, Yokobori S, Bullock RM. Evidence to support mitochondrial neuroprotection, in severe traumatic brain injury. J Bioenerg Biomembr
2015; 47: 133–48
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25358440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang Q. Cyclosporine A inhibits breast cancer cell growth by downregulating the expression of pyruvate kinase subtype M2. Int J Mol Med
2012; 30: 302–8. 10.3892/ijmm.2012.989
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijmm.2012.989</ArticleId>
            <ArticleId IdType="pubmed">22580449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rimmerman N, Ben‐Hail D, Porat Z, Juknat A, Kozela E, Daniels MP, Connelly PS, Leishman E, Bradshaw HB, Shoshan‐Barmatz V, Vogel Z. Direct modulation of the outer mitochondrial membrane channel, voltage‐dependent anion channel 1 (VDAC1) by cannabidiol: a novel mechanism for cannabinoid‐induced cell death. Cell Death Dis
2013; 4: e949
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3877544</ArticleId>
            <ArticleId IdType="pubmed">24309936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ryan D, Drysdale AJ, Lafourcade C, Pertwee RG, Platt B. Cannabidiol targets mitochondria to regulate intracellular Ca2+ levels. J Neurosci
2009; 29: 2053–63
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6666323</ArticleId>
            <ArticleId IdType="pubmed">19228959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Massi P, Solinas M, Cinquina V, Parolaro D. Cannabidiol as potential anticancer drug: cannabidiol and cancer. Br J Clin Pharmacol
2013; 75: 303–12
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3579246</ArticleId>
            <ArticleId IdType="pubmed">22506672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Takahashi KA, Linden DJ. Cannabinoid receptor modulation of synapses received by cerebellar Purkinje cells. J Neurophysiol
2000; 83: 1167–80
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10712447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bernard C, Milh M, Morozov YM, Ben‐Ari Y, Freund TF, Gozlan H. Altering cannabinoid signaling during development disrupts neuronal activity. Proc Natl Acad Sci U S A
2005; 102: 9388–93
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1166590</ArticleId>
            <ArticleId IdType="pubmed">15964987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Keating GM. Delta‐9‐tetrahydrocannabinol/cannabidiol oromucosal spray (Sativex®): a review in multiple sclerosis‐related spasticity. Drugs
2017; 77: 563–74
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28293911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Orange D, Frank M, Tian S, Dousmanis A, Marmur R, Buckley N, Parveen S, Graber JJ, Blachère N, Darnell RB. Cellular immune suppression in paraneoplastic neurologic syndromes targeting intracellular antigens. Arch Neurol
2012; 69: 1132–40
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3721351</ArticleId>
            <ArticleId IdType="pubmed">22566506</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
